Skip to main content
Premium Trial:

Request an Annual Quote

Tute Genomics Inks NGS Test Analytics Deal with Lineagen

NEW YORK (GenomeWeb) – Tute Genomics announced that it will provide next-generation sequencing analytics for a molecular diagnostic test being developed by Lineagen for developmental delay, autism spectrum disorders, and other disorders of childhood development.

Provo, Utah-based Tute said that it has developed a next-gen sequencing analytics platform that can rapidly and accurately analyze whole-exome data and generate customized clinical reports. The firm noted that its CEO Reid Robinson has expertise in ASD genetics, having conducted gene-finding studies as a researcher at the University of Utah.

Salt Lake City-based Lineagen currently provides integrated testing, counseling, and developmental screening services for the early diagnostic evaluation of patients with ASD and other childhood development disorders. Its flagship product is called FirstStepDx Plus, which includes genetic counseling, a customized chromosomal microarray analysis, and a personalized report.

It expects to launch its NextStepDx Plus NGS-based test, which will make use of Tute's analytics, later this year. Financial and other terms of the alliance were not disclosed.

"Our new test identifies previously unknown genetic variants that confer a genetic risk of developing ASD, which Lineagen validated along with The Children's Hospital of Philadelphia and the University of Utah," Linagen CEO Michael Paul said in a statement. He added that the firm's test together are "expected to deliver the highest clinical detection rate clinically available for ASD and other disorders of childhood development."